Credit: Shutterstock photoLoxo Oncology, a biotech developing small molecule therapeutics to treat solid tumors, announced terms for its IPO on Monday. The Stamford, CT-based company plans to raise $57 million by offering 4.4 million shares at a price range of $12 to $14. At the midpoint of the proposed range, it would command a fully diluted market value of $211 million.
Loxo Oncology, which was founded in 2013, plans to list on the NASDAQ under the symbol LOXO. Cowen & Company and Stifel are the joint bookrunners on the deal. It is expected to price during the week of July 28, 2014.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
